Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELP-p21
- Development stage
- Preclinical
- Lead developer
- University of Mississippi Medical Center
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ELP-p21 is a thermally responsive macromolecular conjugate consisting of an elastin-like polypeptide (ELP) carrier fused to a p21-derived therapeutic peptide. The ELP component provides a phase-transition property, allowing the construct to remain soluble at physiological temperatures but aggregate and accumulate in tissues subjected to local hyperthermia (above 40°C). The p21 peptide component is designed to inhibit the cell cycle at the G1/S transition by mimicking the activity of the endogenous cyclin-dependent kinase inhibitor p21 (WAF1/CIP1). Unlike its counterpart Bac-ELP-p21, ELP-p21 lacks a cell-penetrating peptide (CPP), relying on passive targeting and thermal accumulation for tumor uptake. It has been investigated primarily in preclinical models of pancreatic cancer.
- Other names
- Elastin-like Polypeptide-p21
02
Targets
CDK1 (Cyclin-dependent kinase 1)Cyclin–CDK3 (Cyclin–Cyclin-dependent kinase 3 complex)CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on ELP-p21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELP-p21.